Latest Southeast Asia News

Estrella Resources has announced a substantial maiden JORC (2012) inferred limestone resource of 621 million tonnes at its Werumata project in Timor-Leste, highlighting multiple product streams and significant upside potential.

Comvita has completed a $40.5 million capital raise combining a $30 million Rights Offer and a $10.5 million Strategic Placement, welcoming Singapore’s F&N Ventures as a near 20% strategic investor.

Pacific Edge is raising NZ$24 million to shore up its finances and support a crucial Medicare re-coverage bid following a steep revenue drop after losing Medicare reimbursement for its bladder cancer test. The company eyes a draft Medicare policy by September 2026 as a potential turning point.

Fluence Corporation Limited (ASX: FLC) reports a 52% revenue surge in FY2025 driven by strategic growth in Smart Product Solutions and recurring revenue, alongside progress on a major Ivory Coast water treatment plant.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

Comvita has secured the minimum NZ$25 million capital raise required to activate its refinancing plan, driven by strong shareholder participation and Fraser and Neave’s near 20% stake. The Rights Offer closes today, setting the stage for debt repayment and financial restructuring.

Xamble Group has secured A$0.67 million through a discounted placement to fund the integration of YToday and drive AI-powered cost efficiencies, aiming to sharpen its path to profitability.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

Jayride Group continues its pivot to a SaaS mobility platform across Australasia and Southeast Asia, managing tight cash flow and planning a capital raise to sustain operations and support ASX reinstatement.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

DXN Limited posted a 47.5% revenue increase to $3.7 million in Q3 FY26, buoyed by a surge in modular data centre projects and a growing pipeline of 891 identified contracts. The company advanced its Asia-Pacific footprint through a JV in Indonesia and a Malaysian manufacturing push, while securing a $5.3 million Cable Landing Station contract in Latin America.

Osteopore Limited posted a 10% quarter-on-quarter revenue increase to AUD 754K in Q1 CY26, driven by new distribution deals across China, Latin America, and Hong Kong, alongside launching 3D printing services and securing innovative bone graft technologies in Asia Pacific.